Unicycive Therapeutics announces publication of OLC trial data

Unicycive Therapeutics (UNCY) announced the publication of trial data describing the safety and tolerability of oxylanthanum carbonate, OLC, in chronic kidney disease, CKD, patients on dialysis in the Clinical Journal of the American Society of Nephrology. The publication, entitled “A Phase 2 Clinical Trial of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia,” examines the safety and tolerability of OLC at clinically effective doses with a goal serum phosphate concentration of less than or equal to5.5 mg/dL. OLC was well tolerated and enabled serum phosphate control in greater than90% of patients with a low pill burden. Pharmacokinetic analysis showed that systemic absorption of OLC was minimal to none in CKD patients. Key Findings: More than 90% of patients with hyperphosphatemia taking OLC achieved effective phosphate control. Two-thirds of patients required three or fewer OLC tablets per day to achieve target serum phosphate levels, with most requiring no more than one tablet with each meal. OLC was well tolerated in CKD patients on dialysis.